Abstract:Diabetes is a common metabolic disorder marked by unusually high plasma glucose levels, which can lead to serious consequences such as retinopathy, diabetic neuropathy and cardiovascular disease. One of the most efficient ways to reduce postprandial hyperglycemia (PPHG) in diabetes mellitus, especially insulin-independent diabetes mellitus, is to lower the amount of glucose that is absorbed by inhibiting carbohydrate hydrolyzing enzymes in the digestive system, such as α-glucosidase and α-amylase. α-Glucosidase is a crucial enzyme that catalyzes the final stage of carbohydrate digestion. As a result, α-glucosidase inhibitors can slow D-glucose release from complex carbohydrates and delay glucose absorption, resulting in lower postprandial plasma glucose levels and control of PPHG. Many attempts have been made in recent years to uncover efficient α-glucosidase inhibitors from natural sources to build a physiologic functional diet or lead compound for diabetes treatment. Many phytoconstituent α-glucosidase inhibitors have been identified from plants, including alkaloids, flavonoids, anthocyanins, terpenoids, phenolic compounds, glycosides and others. The current review focuses on the most recent updates on different traditional/medicinal plant extracts and isolated compounds' biological activity that can help in the development of potent therapeutic medications with greater efficacy and safety for the treatment of type 2 diabetes or to avoid PPHG. For this purpose, we provide a summary of the latest scientific literature findings on plant extracts as well as plant-derived bioactive compounds as potential α-glucosidase inhibitors with hypoglycemic effects. Moreover, the review elucidates structural insights of the key drug target, α-glucosidase enzymes, and its interaction with different inhibitors.

Progress on Glucosidase Inhibitors

Progress in Sodium-glucose Co-transporter-2 Inhibitors: the New Target for Treatment of Type 2 Diabetes

Dipeptidyl Peptidase IV(DPP IV): a Novel Emerging Target for the Treatment of Type 2 Diabetes

Antidiabetic drugs with α-glucosidase inhibition activities

Recent Advances in Non-Peptidomimetic Dipeptidyl Peptidase 4 Inhibitors: Medicinal Chemistry and Preclinical Aspects

A review on the in vitro and in vivo screening of α-glucosidase inhibitors

Progress in Α-Glucosidase Inhibitor and Application Prospect of Inhibitors from Food

Recent Advances in Synthetic Α‐glucosidase Inhibitors

Research Progress Review on Α-Glucosidase Inhibitor in Food

Progress on research of α-glucosidase inhibitor from herbal medicines

Recent Updates on Phytoconstituent Alpha-Glucosidase Inhibitors: An Approach Towards the Treatment of Type Two Diabetes

Novel DPP-4 Inhibitors Against Diabetes

New selective inhibitors of α‐glucosidase for the treatment of type 2 diabetes mellitus

Discovery of New α-Glucosidase Inhibitors: Structure-Based Virtual Screening and Biological Evaluation

Advances of Dipeptidyl Peptidase Ⅳ Inhibitors in Diabetes Mellitus

Advances of new antidiabetic drugs

Recent Advances in the Development of Alpha-Glucosidase and Alpha-Amylase Inhibitors in Type 2 Diabetes Management: Insights from In silico to In vitro Studies

Progress on Research of Screening Methods for Alpha-Glucosidase Inhibitors from Chinese Medicinal Herbs

A New Potent Inhibitor Against Α-Glucosidase Based on an in Vitro Enzymatic Synthesis Approach

Synthetic approaches and clinical application of small-molecule inhibitors of sodium-dependent glucose transporters 2 for the treatment of type 2 diabetes mellitus

Research Progress of Glucagon-Like Peptide-1 in the Treatment of Type 2 Diabetes Mellitus